ArticleFrontiers in aging neuroscience2026
Transsynaptic complex dysfunction in the hippocampus of Alzheimer's disease patients.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) involves not only amyloid-β and tau pathology but synaptic dysfunction and impaired autophagy, though the underlying mechanisms and their relationship to AD progression are not well understood. Transsynaptic complexes involving presynaptic neurexins (Nrxn1/2/3), secreted cerebellins (Cbln1/2/3/4), and postsynaptic glutamate delta receptors (GluD1/2) play critical roles in organizing synapses and synaptic plasticity. Studies in pain models have reported that treatment with recombinant Cbln1 rescues AMPA glutamate receptor imbalance, promotes autophagy, and inhibits hyperexcitability and pain behaviors. Here we tested the novel hypothesis that dysregulation of Cbln-GluD-based transsynaptic complexes may occur in the brain of AD patients, providing insights into disease progression and potential avenues for therapeutic development. Methods: We analyzed human hippocampal tissues from the TTUHSC Garrison Brain Bank and the NIH NeuroBioBank for expression of transsynaptic complex components in addition to autophagy and neuroplasticity pathways. Their expression in hippocampus was compared between control samples of Braak stages 0/1 and AD samples showing either mild (Braak stage 2) or severe (Braak stages 5/6) neurofibrillary tangle pathology. Co-immunoprecipitation was used to examine protein-protein interactions. Results: We found significantly decreased protein levels of Cbln1 and GluD2 in AD hippocampus. In the autophagy pathway, PIST and beclin-1 were decreased in AD hippocampus. Co-immunoprecipitation revealed interactions between GluD1 and PIST and between PIST and beclin-1, suggesting possible regulatory interactions between transsynaptic complex elements and autophagy in human hippocampus. We further observed decreased BDNF, consistent with diminished neuroplasticity. Finally, cofilin phosphorylation was decreased in AD, suggesting disruption of trafficking and formation of cofilin-actin rods. Discussion: These results suggest that the homeostasis of signaling molecules important for synaptic integrity is disrupted in the human hippocampus at both early- and late-stage AD. The loss of transsynaptic complex expression is accompanied by the downregulation of autophagy and neuroplasticity markers that are known to be linked to AD pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.